
|Articles|September 26, 2007
DEA classifies oripavine as Schedule II
Oripavine is designated a Schedule II controlled substance by the Drug Enforcement Administration
Advertisement
DEA has issued a final rule designating oripavine as a basic class in Schedule II of the Controlled Substances Act. The agency explained that there's no need to promulgate this rule as a proposal first because oripavine is already subject to control under Schedule II as a derivative of thebaine, a natural constituent of opium. DEA is taking this new action in order to comply with international treaty obligations. The final rule took effect on Sept. 24. For more information on the rule, go to
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
Long-Term Adverse Effects After COVID-19 Vaccination Vary by Brand
2
Individualized Approach Helps When Intensifying GLP-1 Therapy in T2D
3
Meta-Analysis Identifies 5 Risk Factors for Post-COVID-19 Condition
4
Model Finds Weight Regain After Stopping Semaglutide or Tirzepatide
5







































